维普期刊资源整合服务平台（V6.5）

39篇 您的检索式：作者名="Ott PA"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase Ⅰ trial显示文摘	Ott PA Chang J Madden K	2013	Cancer Chemother Phar- macol2013，71，1：	1
2	Novel therapeutics for melanoma 显示文摘	Seetharamu N Ott PA Pavlick AC	2009	Expert Rev Anticancer Ther2009，9，6：	1
3	CTLA-4 and PD-1/PD-L1 blockade : new immunotherapeutic modalities with durable clinical benefit in melanoma patients 显示文摘	Ott PA Hodi FS Robert C	2013	Clin Cancer Res2013，19，19：	1
4	Islet-cell antigenreactive T cells show different expansion rates and Th1 /Th2 differentiation in type 1 diabetic patients and healthy controls显示文摘	Ott PA Herzog BA Quast S	2005	Clin Immunol2005，115，2：	1
5	New developments in the treatment of metastatic melanoma:role of dabrafenih-trametinib combination therapy显示文摘	Luke J J Ott PA	2014	Drug Heahhe Patient Saf2014，6，：	1
6	Phase I I II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma 显示文摘	Ott PA Carvajal RD Pandit-Taskar N	2013	Invest New Drugs2013，31，2：	1
7	Small-molecule protein kinase inhibitors and their effects on the immune system:implications for cancer treatment 显示文摘	Ott PA Adams S	2011	Im- munotherapy2011，3，2：	1
8	CTLA-4 and PD-1/PD-L1 blockade : new immunotherapeutic modalities with durable clinical benefit in melanoma patients 显示文摘	Ott PA Hodi FS Robert C	2013	Clin Cancer Res2013，19，19：	1
9	Pembrolizumab (MK- 3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC):prcliminary safety and efficacy results from KEYNOTE-028显示文摘	Ott PA Fernandez MEE Hiret S	2015	J Clin Oncol2015，，：	1
10	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients显示文摘	Ott PA Hodi FS Robert C	2013	Clin Cancer Res2013，19，19：	1
11	Phase I /II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma显示文摘	Ott PA Carvajal RD Pandit-Taskar N	2013	Invest New Drugs2013，31，2：	1
12	Novel therapeutics for mela- noma 显示文摘	Seetharamu N Ott PA Pavlick AC	2009	Expert Rev Anticancer Ther2009，9，6：	1
13	CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic modalities with durable Clinical Benefit in Melanoma Patients显示文摘	Ott PA Hodi FS Robert C	2013	Clin Cancer Res2013，19，19：	1
14	HLA - binding properties of tumor neoepitopes in humans 显示文摘	Fritseh EF Rajasagi M Ott PA	2014	Cancer Immunol Res2014，2，6：	1
15	Inhibition of both BRAF and MEK in BRAF (V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties 显示文摘	Ott PA Henry T Baranda S J	2013	Cancer Immunol Immunother2013，62，4：	1
16	Phase/study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma显示文摘	Ott PA Hamid O Pavlick AC	2014	J Clin Oncol2014，32，32：	1
17	The biology and clinical development of MEK inhibitors for cancer显示文摘	Luke J J Ott PA Shapiro GI	2014	Drugs2014，7，4：	1
18	Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes显示文摘	Meierhoff G Ott PA Lehmann PV	2002	Diabetes Metab Res Rev2002，18，：	1
19	CD4^+CD25^+ regulatory T cells control the progression from periinsulitis to destructive insulitis in murine type 1 diabetes显示文摘	Ott PA Anderson MR Tary-Lehmann M	2005	Cell Immunol2005，235，1：	1
20	Cytokine detection by ELISPOT:relevance for immunological studies in type Ⅰ diabetes显示文摘	Meierhoff G Ott PA Lehmann PV	2002	Diabetes Metab Res Rev2002，18，5：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示